Simulations Plus (NASDAQ:SLP) Upgraded at Wall Street Zen

Simulations Plus (NASDAQ:SLP) was upgraded by equities researchers at Wall Street Zen from a “hold” rating to a “buy” rating in a note issued to investors on Saturday.

SLP has been the subject of a number of other reports. TD Cowen restated a “hold” rating on shares of Simulations Plus in a research note on Thursday, January 8th. Citigroup reiterated a “market perform” rating on shares of Simulations Plus in a research note on Tuesday, January 6th. Zacks Research downgraded shares of Simulations Plus from a “strong-buy” rating to a “hold” rating in a report on Monday, February 2nd. Finally, BTIG Research lowered shares of Simulations Plus from a “buy” rating to a “neutral” rating in a research report on Thursday, December 18th. Three research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Simulations Plus presently has an average rating of “Hold” and a consensus target price of $25.00.

Simulations Plus Trading Down 0.3%

Shares of SLP opened at $11.67 on Friday. The firm has a fifty day simple moving average of $14.75 and a two-hundred day simple moving average of $16.23. The firm has a market cap of $235.15 million, a PE ratio of -3.65 and a beta of 1.17. Simulations Plus has a 1-year low of $11.16 and a 1-year high of $36.45.

Simulations Plus (NASDAQ:SLP) last released its quarterly earnings results on Thursday, January 8th. The technology company reported $0.13 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.18 by ($0.05). The firm had revenue of $18.42 million during the quarter, compared to analysts’ expectations of $18.05 million. Simulations Plus had a positive return on equity of 14.02% and a negative net margin of 81.66%.During the same quarter last year, the business earned $0.17 earnings per share. As a group, research analysts forecast that Simulations Plus will post 1.09 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. North Star Investment Management Corp. raised its position in shares of Simulations Plus by 195.6% during the third quarter. North Star Investment Management Corp. now owns 168,130 shares of the technology company’s stock valued at $2,534,000 after buying an additional 111,255 shares during the last quarter. Tributary Capital Management LLC lifted its holdings in shares of Simulations Plus by 214.7% in the third quarter. Tributary Capital Management LLC now owns 1,136,980 shares of the technology company’s stock worth $17,134,000 after buying an additional 775,704 shares in the last quarter. Royce & Associates LP boosted its position in shares of Simulations Plus by 31.6% during the third quarter. Royce & Associates LP now owns 348,758 shares of the technology company’s stock worth $5,256,000 after acquiring an additional 83,758 shares during the last quarter. Stephens Investment Management Group LLC grew its stake in Simulations Plus by 46.3% during the third quarter. Stephens Investment Management Group LLC now owns 392,840 shares of the technology company’s stock valued at $5,920,000 after acquiring an additional 124,264 shares in the last quarter. Finally, Herald Investment Management Ltd purchased a new position in Simulations Plus during the third quarter valued at $3,016,000. 78.08% of the stock is owned by hedge funds and other institutional investors.

Simulations Plus Company Profile

Simulations Plus, Inc (NASDAQ: SLP) specializes in advanced modeling and simulation software tailored to the pharmaceutical, biotechnology and chemical industries. The company’s flagship products include ADMET Predictor, a quantitative structure-activity relationship (QSAR) tool for predicting absorption, distribution, metabolism, excretion and toxicity properties, and GastroPlus, a physiologically based pharmacokinetic (PBPK) modeling platform for simulating drug absorption and pharmacokinetics.